Related Experiment Video

Updated: Jan 8, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

Tarlatamab for small-cell lung cancer

Sabina Antoniu1, Theodor Penisoara2, Stefan Rascu3

  • 1Department of Medicine II-Nursing, University of Medicine and Pharmacy, Grigore T Popa, Iasi, Romania.

Expert Opinion on Biological Therapy
|December 16, 2025
PubMed
Abstract

Insights

Tarlatamab is an effective bispecific antibody for extensive small-cell lung cancer (SCLC), particularly in relapsed or progressed cases. Further assessment in limited SCLC, alone or combined, is supported by current data.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Small-cell lung cancer (SCLC) is an aggressive malignancy often expressing DLL3.
  • Tarlatamab is a bispecific antibody targeting DLL3, designed to block downstream pathways and enhance antitumor immunity.

Purpose of the Study:

  • To review the pharmacology and clinical data of tarlatamab.
  • To evaluate tarlatamab's efficacy in various SCLC settings.

Main Methods:

  • Review of existing pharmacological and clinical trial data for tarlatamab.
  • Analysis of data primarily from SCLC patients, with consideration for other indications in early development.

Main Results:

  • Tarlatamab demonstrates effectiveness, especially in relapsed or progressed extensive SCLC.
  • The drug is currently authorized in the U.S. for extensive SCLC treatment.

Conclusions:

  • Tarlatamab is a valuable therapeutic option for relapsed/progressed SCLC.
  • Existing data support further investigation of tarlatamab in limited SCLC, as monotherapy or in combination.
Keywords:
BITE antibodiesDLL3cytokine releasing syndromeimmune effector cell therapy associated neurotoxicity syndromesmall cell lung cancertarlatamab

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K